Inogen, Inc. (NASDAQ:INGN) Short Interest Down 6.2% in December

Inogen, Inc. (NASDAQ:INGN) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 714,200 shares, a decrease of 6.2% from the December 15th total of 761,300 shares. Based on an average daily volume of 187,000 shares, the short-interest ratio is currently 3.8 days.

Analysts Set New Price Targets

INGN has been the topic of a number of research reports. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Tuesday, January 14th. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, December 20th.

Inogen Trading Down 0.5 %

NASDAQ INGN traded down $0.05 during trading hours on Friday, hitting $10.47. The company’s stock had a trading volume of 149,232 shares, compared to its average volume of 148,305. The stock has a fifty day moving average of $9.53 and a 200 day moving average of $9.94. Inogen has a twelve month low of $5.08 and a twelve month high of $13.33.

Hedge Funds Weigh In On Inogen

Several large investors have recently bought and sold shares of INGN. Divisadero Street Capital Management LP lifted its holdings in Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after purchasing an additional 132,287 shares in the last quarter. AQR Capital Management LLC increased its stake in Inogen by 29.3% in the second quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock valued at $4,642,000 after purchasing an additional 129,307 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Inogen in the second quarter valued at approximately $651,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Inogen in the second quarter valued at approximately $457,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.